Foroni, Letizia

Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers

Maser, R. S., Choudhury, B., Campbell, P. J., Feng, B., Wong, K.-K., Protopopov, A., O’Neil, J., Gutierrez, A., Ivanova, E., Perna, I., et al. (2007) · Nature

Cancer Genomics and DiagnosticsGenomic variations and chromosomal abnormalities

Cited by 377

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., et al. (2019) · The Lancet Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 195

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia

Claudiani, S., Apperley, J. F., Szydlo, R., Khan, A., Nesr, G., Hayden, C., J. Innes, A., Dominy, K., Foskett, P., Foroni, L., et al. (2021) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 42

Assessment of quantitative polymerase chain reaction for BCR–ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?

Dominy, K. M., Claudiani, S., O’Hare, M., Szydlo, R., Gerrard, G., Foskett, P., Foroni, L., Milojkovic, D., Apperley, J. F., & Khorashad, J. (2022) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 11

Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia

Gerrard, G., Foong, H. E., Mudge, K., Alikian, M., Apperley, J. F., & Foroni, L. (2016) · Leukemia Research

Chronic Myeloid Leukemia TreatmentsClinical Laboratory Practices and Quality Control

Cited by 8